ABSTRACT
Hepatitis C virus (HCV) is a major pathogen with approximately 3% of the world's population (over 170 million) infected. Epidemiological studies have shown HCV is associated with an increased risk of cardiovascular and cerebrovascular mortality as well as peripheral arterial disease. This is despite HCV inducing an ostensibly favourable lipid profile with accompanying low classical risk score for atherosclerosis (AS). We discuss possible factors involved in the aetiopathogenesis of atherosclerosis in chronic HCV and hypothesise that an important mechanism underlying the development of AS is the presence of circulating low-density immune complexes that induce an inflammatory response. We suggest that HCV particles may be inducing an antibody response to lipoproteins present in the lipoviral particles and sub-viral particles - a concept similar to the more general 'autoantibody' response to modified LDL. After virologic cure some AS risk factors will recede but an increase in serum cholesterol could result in progression of early atherosclerotic lesions, leaving a legacy from persistent HCV infection that has clinical and therapeutic implications.
Subject(s)
Atherosclerosis/complications , Hepacivirus/pathogenicity , Hepatitis C/complications , Atherosclerosis/diagnosis , Atherosclerosis/virology , Coronary Artery Disease/diagnosis , Disease Progression , Hepacivirus/isolation & purification , Hepatitis C/diagnosis , Humans , Prognosis , Risk Factors , Severity of Illness Index , Viral LoadABSTRACT
Neuro-psychiatric and cognitive disorders are frequent in patients with chronic hepatitis C (CHC) virus (HCV) infection which adversely impact quality of life, antiviral treatment adherence and outcome. HCV has neurotrophic properties and affects lipid metabolism, essential for cognitive function. We evaluated the relationship of lipid profiles with depression and anxiety symptoms and the effects of 12-weeks of therapy with fluvastatin and omega-3 ethyl esters (n-3 PUFA) in a randomised pilot study of CHC prior non-responders. Participants (n = 60) had fasting lipid profiles and assessment of depression and anxiety symptoms using the Hospital Anxiety and Depression Scale (HADS) questionnaire at each study visit. At screening 26/60 (43 %) had HADS-A score ≥8 and 13/60 (22 %) had HADS-D scores ≥8. Depressed patients had significantly lower apolipoprotein-E concentrations (30 mg/l vs 39 mg/l, P = 0.029) than those without depression and a tendency toward lower total cholesterol (3.8 vs 4.4 mmol/l, P = 0.053). 3 patients discontinued lipid-modifying treatment because of worsening depression. However, there was a small but significant improvement in anxiety symptoms after 12-weeks of high-dose (2-4 g daily) n-3 PUFA. In conclusion, depression in CHC is associated with plasma apoE deficiency. We postulate that apoE deficiency disrupts blood brain barrier integrity to promote HCV infection of the CNS. High-dose n-PUFAs may alleviate anxiety in some CHC patients but the use of lipid lowering therapy must be balanced against risks of worsening depression.
Subject(s)
Apolipoproteins E/blood , Depression/blood , Depression/psychology , Hepatitis C, Chronic/blood , Hepatitis C, Chronic/psychology , Adult , Anxiety/blood , Anxiety/drug therapy , Anxiety/psychology , Cholesterol/blood , Depression/drug therapy , Fatty Acids, Monounsaturated/therapeutic use , Female , Fluvastatin , Hepatitis C, Chronic/complications , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Indoles/therapeutic use , Male , Middle Aged , Pilot Projects , Treatment OutcomeABSTRACT
Chronic hepatitis C virus (HCV) infection is associated with an increase in hepatic steatosis and a decrease in serum levels of total cholesterol, low-density lipoprotein cholesterol (LDL) and apolipoprotein B (apoB), the main protein constituent of LDL and very low-density lipoprotein (VLDL). These changes are more marked in HCV genotype 3 infection, and effective treatment results in their reversal. Low lipid levels in HCV infection correlate not only with steatosis and more advanced liver fibrosis but also with non-response to interferon-based therapy. The clinical relevance of disrupted lipid metabolism reflects the fact that lipids play a crucial role in the life cycle of hepatitis C virus. HCV assembly and maturation in hepatocytes depend on microsomal triglyceride transfer protein and apoB in a manner that parallels the formation of VLDL. VLDL production from the liver occurs throughout the day with an estimated 10(18) particles produced every 24 h whilst the estimated hepatitis C virion production rate is 10(12) virions per day. HCV particles in the serum exist as a mixture of complete low-density infectious lipo-viral particles (LVP) and a vast excess of apoB-associated empty nucleocapsid-free sub-viral particles that are complexed with anti-HCV envelope antibodies. Apolipoprotein E (apoE) is also involved in HCV particle morphogenesis and is an essential apolipoprotein for HCV infectivity. ApoE is a critical ligand for the receptor-mediated removal of triglyceride rich lipoprotein (TRL) remnants by the liver. The dynamics of apoB-associated lipoproteins, including HCV-LVP, change post-prandially with an increase in large TRL remnants and very low density HCV-LVP which are rapidly cleared by the liver (at least three HCV receptors are cellular receptors for uptake of TRL remnants). In summary, HCV utilises triglyceride-rich lipoprotein pathways within the liver and the circulation to its advantage.
Subject(s)
Fatty Liver/complications , Hepacivirus/metabolism , Hepatitis C, Chronic/metabolism , Lipids/blood , Apolipoproteins B/blood , Cholesterol/blood , Cholesterol, VLDL/blood , Humans , Lipoproteins, LDL/bloodABSTRACT
Cascade testing using DNA-mutation information is now recommended in the UK for patients with familial hypercholesterolaemia (FH). We compared the detection rate and mutation spectrum in FH patients with a clinical diagnosis of definite (DFH) and possible (PFH) FH. Six hundred and thirty-five probands from six UK centres were tested for 18 low-density lipoprotein receptor gene (LDLR) mutations, APOB p.Arg3527Gln and PCSK9 p.Asp374Tyr using a commercial amplification refractory mutation system (ARMS) kit. Samples with no mutation detected were screened in all exons by single strand conformation polymorphism analysis (SSCP)/denaturing high performance liquid chromatography electrophoresis (dHPLC)/direct-sequencing, followed by multiplex ligation-dependent probe amplification (MLPA) to detect deletions and duplications in LDLR.The detection rate was significantly higher in the 190 DFH patients compared to the 394 PFH patients (56.3% and 28.4%, p > 0.00001). Fifty-one patients had inadequate information to determine PFH/DFH status, and in this group the detection rate was similar to the PFH group (25.5%, p = 0.63 vs PFH). Overall, 232 patients had detected mutations (107 different; 6.9% not previously reported). The ARMS kit detected 100 (44%) and the MLPA kit 11 (4.7%). Twenty-eight (12%) of the patients had the APOB p.Arg3527Gln and four (1.7%) had the PCSK9 p.Asp374Tyr mutation. Of the 296 relatives tested from 100 families, a mutation was identified in 56.1%. In 31 patients of Indian/Asian origin 10 mutations (two previously unreported) were identified. The utility of the ARMS kit was confirmed, but sequencing is still required in a comprehensive diagnostic service for FH. Even in subjects with a low clinical suspicion of FH, and in those of Indian origin, mutation testing has an acceptable detection rate.
Subject(s)
Hypercholesterolemia/genetics , Mutation , Apolipoproteins B/genetics , Genetic Testing , Humans , Hypercholesterolemia/diagnosis , Pilot Projects , Receptors, LDL/genetics , United KingdomABSTRACT
AIMS: Although the limitations of the Friedewald-calculated serum low-density lipoprotein cholesterol (LDL-C) are well recognized, many diabetes and lipid guidelines propose LDL-C as a therapeutic target. The validity of calculated LDL-C in people with Type 1 diabetes (T1DM) is uncertain and the use of alternatives such as non-high-density lipoprotein cholesterol (non-HDL-C) or apolipoprotein measurement unexplored. We have therefore measured LDL-C with the designated reference method and examined some of the potential sources of such bias, including plasma concentrations of other lipids and apolipoproteins. METHODS: Seventy-four people with T1DM and 80 healthy control subjects were recruited. Fasting samples were collected for analysis of lipid profiles by a beta-quantification (BQ) reference method and by routine laboratory methods including direct HDL-C and calculation of LDL-C using the Friedewald formula. RESULTS: Overall, Friedewald LDL-C was 0.29 +/- 0.02 (mean +/- SE) mmol/l (P < 0.001) lower in the two groups than by the BQ method. This resulted in misclassification of approximately 50% of people with a calculated LDL-C < 2.0 mmol/l. Overestimation of HDL-C by the routine assay [0.08 +/- 0.01 mmol/l (P < 0.001)] accounted for approximately 28% of the error in calculation of LDL-C and the remainder appeared to be as a result of triglyceride in lipoprotein particles other than very-low-density lipoprotein (VLDL). Correlation of non-HDL-C with apolipoprotein B was better than LDL-C with apolipoprotein B for both assays in both diabetic and non-diabetic populations. CONCLUSIONS: Calculated LDL-C is unsuitable as a therapeutic target in T1DM. Consideration should be give to the greater use of apolipoprotein B or non-HDL-C in clinical practice.
Subject(s)
Apolipoproteins B/metabolism , Cholesterol, LDL/metabolism , Diabetes Mellitus, Type 1/metabolism , Triglycerides/metabolism , Adolescent , Adult , Analysis of Variance , Diabetes Mellitus, Type 1/physiopathology , Fasting/physiology , Female , Humans , Male , Reference Values , Reproducibility of Results , Young AdultABSTRACT
BACKGROUND: National guidelines have been developed in the UK to reduce coronary heart disease mortality. This audit assesses provision of lipid analyses by UK Clinical Biochemistry services to support their implementation. METHODS: Audit standards were derived from published guidelines. A questionnaire based on these was circulated to all UK Clinical Biochemistry laboratories. RESULTS: Of 108 replies, routine lipid profiles included triglycerides, HDL-, LDL-cholesterol and total:HDL cholesterol ratio in 98, 85, 72 and 44%, respectively. Only 33% and 27% analysed triglycerides and HDL, respectively, when asked simply to measure cholesterol. Seventy-six percent of the reports stated whether specimens were collected after fasting. For primary prevention, 46% of laboratories stated results should be interpreted in association with other risk factors; 20% referred explicitly to national/local guidelines. Only 19 laboratories quoted secondary prevention treatment thresholds for total cholesterol or LDL-cholesterol. Sixty laboratories occasionally added extra tests and/or interpretive comments. Eight laboratories appeared to provide no input from senior medical/scientific staff into report validation. CONCLUSIONS: These results indicate scope for improvement in the provision of lipid analyses and of information to support their interpretation. We recommend laboratories should routinely provide LDL- and non-HDL-cholesterol results, and that reports should quote treatment thresholds/targets in keeping with current guidelines.
Subject(s)
Laboratories/organization & administration , Lipids/blood , Guidelines as Topic , Humans , Lipids/classification , Surveys and Questionnaires , United KingdomABSTRACT
Liver and skeletal muscle triglyceride stores are elevated in type 2 diabetes and correlate with insulin resistance. As postprandial handling of dietary fat may be a critical determinant of tissue triglyceride levels, we quantified postprandial fat storage in normal and type 2 diabetes subjects. Healthy volunteers (n = 8) and diet-controlled type 2 diabetes subjects (n = 12) were studied using a novel 13C magnetic resonance spectroscopy protocol to measure the postprandial increment in liver and skeletal muscle triglyceride following ingestion of 13C-labeled fatty acids given with a standard mixed meal. The postprandial increment in hepatic triglyceride was rapid in both groups (peak increment controls: +7.3 +/- 1.5 mmol/l at 6 h, P = 0.002; peak increment diabetics: +10.8 +/- 3.4 mmol/l at 4 h, P = 0.009). The mean postprandial incremental AUC of hepatic 13C enrichment between the first and second meals (0 and 4 h) was significantly higher in the diabetes group (6.1 +/- 1.4 vs. 1.7 +/- 0.6 mmol x l(-1) x h(-1), P = 0.019). Postprandial increment in skeletal muscle triglyceride in the control group was small compared with the diabetic group, the mean 24-h postprandial incremental AUC being 0.2 +/- 0.3 vs. 1.7 +/- 0.4 mmol x l(-1) x h(-1) (P = 0.009). We conclude that the postprandial uptake of fatty acids by liver and skeletal muscle is increased in type 2 diabetes and may underlie the elevated tissue triglyceride stores and consequent insulin resistance.
Subject(s)
Diabetes Mellitus, Type 2/metabolism , Liver/metabolism , Muscle, Skeletal/metabolism , Triglycerides/metabolism , 3-Hydroxybutyric Acid/blood , Area Under Curve , Blood Glucose/metabolism , Chylomicrons , Diabetes Mellitus, Type 2/blood , Dietary Fats/metabolism , Fatty Acids, Nonesterified/blood , Fatty Acids, Nonesterified/metabolism , Female , Glycerol/blood , Humans , Insulin/blood , Insulin Resistance , Lactic Acid/blood , Lipoproteins/blood , Magnetic Resonance Imaging , Male , Middle Aged , Postprandial Period/physiology , Triglycerides/bloodABSTRACT
BACKGROUND: We examined the development of new diabetes mellitus in men aged 45 to 64 years during the West of Scotland Coronary Prevention Study. METHODS AND RESULTS: Our definition of diabetes mellitus was based on the American Diabetic Association threshold of a blood glucose level of >/=7.0 mmol/L. Subjects who self-reported diabetes at baseline or had a baseline glucose level of >/=7.0 mmol/L were excluded from the analyses. A total of 5974 of the 6595 randomized subjects were included in the analysis, and 139 subjects became diabetic during the study. The baseline predictors of the transition from normal glucose control to diabetes were studied. In the univariate model, body mass index, log triglyceride, log white blood cell count, systolic blood pressure, total and HDL cholesterol, glucose, and randomized treatment assignment to pravastatin were significant predictors. In a multivariate model, body mass index, log triglyceride, glucose, and pravastatin therapy were retained as predictors of diabetes in this cohort. CONCLUSIONS: We concluded that the assignment to pravastatin therapy resulted in a 30% reduction (P:=0.042) in the hazard of becoming diabetic. By lowering plasma triglyceride levels, pravastatin therapy may favorably influence the development of diabetes, but other explanations, such as the anti-inflammatory properties of this drug in combination with its endothelial effects, cannot be excluded with these analyses.
Subject(s)
Anticholesteremic Agents/therapeutic use , Coronary Disease/prevention & control , Diabetes Mellitus/prevention & control , Pravastatin/therapeutic use , Blood Glucose , Body Mass Index , Cohort Studies , Diabetes Mellitus/blood , Humans , Male , Middle Aged , Multivariate Analysis , Prospective Studies , Risk Factors , Triglycerides/bloodABSTRACT
In normal subjects, endogenous glucose production (EGP) is usually assumed to be completely suppressed during euglycaemic clamp studies performed at high insulin levels (> 100 mU L-1). However, this assumption is based on non-steady-state tracer measurements of EGP which are prone to negative errors. We have used purified [6-(3)H]glucose in an optimal tracer infusion protocol to assess the suppression of EGP during 4 h euglycaemic clamps in eight normal men. An insulin infusion rate of 5 mU kg-1 min-1 was chosen to achieve supraphysiological (> 500 mU L-1) plasma insulin concentrations. Using a labelled exogenous glucose infusion, plasma glucose (mean +/- SEM 5.3 +/- 0.1 mmol L-1) and glucose specific activities (mean 100 +/- 3% of basal) were maintained constant from 80 to 240 min. During hyperinsulinaemia, isotopically determined glucose appearance rates (Ra) were greater than glucose infusion rates (GIR) throughout the euglycaemic clamp period (P < 0.001) and EGP (Ra-GIR) was always greater than zero. In seven of the eight subjects studied EGP was partly suppressed but showed a wide variation (EGP 5 to 91% of basal at 80-120 min and 12 to 87% of basal at 200-240 min) while in one subject EGP rose above basal (by 72% at 80-120 min and 49% at 200-240 min). We conclude that EGP is not completely suppressed during euglycaemic clamps at high insulin levels.
Subject(s)
Glucose/biosynthesis , Insulin/blood , Adult , Gluconeogenesis , Glucose Clamp Technique , Humans , MaleABSTRACT
Increased glucose/glucose-6-phosphate (G/G6P) substrate cycle activity may be an early marker of disordered hepatic glucose metabolism. To investigate the effects of glucocorticoids on G/G6P cycle activity and insulin resistance, we studied eight normal subjects using the euglycemic glucose clamp technique with high pressure liquid chromatography-purified [2(3)H]- and [6-3H]glucose tracers at insulin infusion rates of 0.4 and 2.0 mU/kg.min after 24-h cortisol (2 micrograms/kg.min) and saline infusions. Endogenous glucose production ([6-3H]glucose) was greater after cortisol than saline in the postabsorptive state (13.3 +/- 0.5 vs. 12.2 +/- 0.5 mumol/kg.min; P < 0.05) and during 0.4-mU insulin infusion (10.5 +/- 0.7 vs. 5.0 +/- 0.8 mumol/kg.min; P < 0.005). During 2.0-mU insulin infusion, endogenous glucose production was suppressed similarly (5.1 +/- 0.4 vs. 4.1 +/- 0.5 mumol/kg.min), but glucose disappearance was less after cortisol than saline (38.7 +/- 3.5 vs. 64.6 +/- 4.3 mumol/kg.min; P < 0.001). G/G6P cycle activity after cortisol and saline was similar in the postabsorptive state and during 0.4 mU insulin. During 2.0 mU insulin, cycle activity was greater after cortisol than saline (3.6 +/- 0.9 vs. 0.8 +/- 0.5 mumol/kg.min; P < 0.005). In conclusion, cortisol induces hepatic insulin resistance without significantly changing G/G6P cycle activity. At high glucose turnover rates, G/G6P cycle activity is increased by cortisol; however, reduced glucose disappearance is the main cause of impaired insulin action.
Subject(s)
Glucose/metabolism , Glucosephosphates/metabolism , Hydrocortisone/pharmacology , Insulin/pharmacology , Absorption , Adult , Blood Glucose/analysis , Female , Glucose Clamp Technique , Glucose-6-Phosphate , Humans , MaleSubject(s)
Phosphates/blood , Potassium Compounds , Female , Humans , Middle Aged , Phosphates/therapeutic use , Potassium/therapeutic useABSTRACT
It has been suggested that increased glucose/glucose 6-phosphate substrate cycling impairs net hepatic glucose uptake in Type 2 (non-insulin-dependent) diabetes mellitus and contributes to hyperglycaemia. To investigate glucose/glucose 6-phosphate cycle activity and insulin action in Type 2 diabetes we studied eight patients and eight healthy control subjects, using the euglycaemic glucose clamp and isotope dilution techniques with purified [2-3H]- and [6-3H] glucose tracers, in the post-absorptive state and eight patients and five healthy control subjects during consecutive insulin infusions at rates of 0.4 and 2.0 mU.kg-1 x min-1. [2-3H]glucose and [6-3H]glucose radioactivity in plasma samples were determined using selective enzymatic detritiation, allowing calculation of glucose turnover rates for each isotope, the difference being glucose/glucose 6-phosphate cycling. Endogenous glucose production ([6-3H]glucose) was greater in diabetic than control subjects in the post-absorptive state (15.6 +/- 1.5 vs 11.3 +/- 0.4 mumol.kg-1 x min-1, p < 0.05) and during the 0.4 mU insulin infusion (10.1 +/- 1.3 vs 5.2 +/- 0.3 mumol.kg-1 x min-1, p < 0.01) indicating hepatic insulin resistance. Glucose/glucose 6-phosphate cycling was significantly greater in diabetic than in control subjects in the post-absorptive state (2.6 +/- 0.4 vs 1.6 +/- 0.2 mumol.kg-1 x min-1, p < 0.05) but not during the 0.4 mU insulin infusion (2.0 +/- 0.4 vs 2.0 +/- 0.3 mumol.kg-1 x min-1).(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Diabetes Mellitus, Type 2/physiopathology , Glucose/physiology , Glucosephosphates/physiology , Insulin Resistance/physiology , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/metabolism , Female , Glucose/metabolism , Glucose-6-Phosphate , Glucosephosphates/metabolism , Humans , Hyperinsulinism/physiopathology , Insulin/pharmacology , Male , Middle Aged , TritiumABSTRACT
Increased activity of the hepatic glucose-glucose 6-phosphate (G/G-6-P) cycle is associated with hepatic and peripheral insulin resistance in acromegaly. To determine whether a similar association occurs after short-term growth hormone (GH) elevation within the physiological range, two-step euglycemic hyperinsulinemic clamps were performed in normal human males after 12-h GH (2.2 ng.kg-1 x h-1) and control infusions. G/G-6-P cycle activity and endogenous glucose production (EGP) were determined by [2-3H]- and [6-3H]-glucose using labeled exogenous glucose infusions and selective enzymatic detritiation. GH increased levels of circulating lipid intermediates despite a twofold increase in basal insulin (P < 0.005), but plasma glucose, EGP, and G/G-6-P cycle activity were unchanged. GH impaired insulin suppression of EGP and lipid intermediates and impaired insulin stimulation of glucose disposal, but G/G-6-P cycle activity was unchanged. We conclude that increased activity of the G/G-6-P cycle does not contribute to the hepatic insulin resistance induced by GH under these conditions but that changes in fatty acid metabolism may be partly responsible for the impairment in hepatic and peripheral insulin action.
Subject(s)
Blood Glucose/metabolism , Glucosephosphates/blood , Growth Hormone/pharmacology , Insulin/pharmacology , Adult , Glucose Clamp Technique , Glucose-6-Phosphate , Hormones/blood , Humans , Infusions, Intravenous , Kinetics , Male , Osmolar Concentration , Reference ValuesABSTRACT
Peripheral insulin resistance is a feature of essential hypertension, but there is little information about hepatic insulin sensitivity. To investigate peripheral and hepatic insulin sensitivity and activity of the hepatic glucose/glucose 6-phosphate (G/G6P) substrate cycle in essential hypertension, euglycemic glucose clamps were performed in eight untreated patients and eight matched controls at insulin infusion rates of 0.2 and 1.0 mU.kg-1.min-1. A simultaneous infusion of (2(3)H)- and (6(3)H)glucose, combined with a selective detritiation procedure, was used to determine glucose turnover, the difference being G/G6P cycle activity. Endogenous hepatic glucose production (EGP) determined with (6(3)H)glucose was similar in hypertensive and control groups in the postabsorptive state (11.0 +/- 0.3 v 10.9 +/- 0.3 mumol.kg-1.min-1) and with the 0.2 mU insulin infusion (4.9 +/- 0.5 v 4.0 +/- 0.8 mumol.kg-1.min-1). With the 1.0 mU insulin infusion, glucose disappearance determined with (6(3)H)glucose was lower in the hypertensive group (21.8 +/- 2.4 v 29.9 +/- 2.4 mumol.kg-1.min-1, P less than .001). G/G6P cycle activity was similar both in the postabsorptive state (2.2 +/- 0.4 v 2.7 +/- 0.4 mumol.kg-1.min-1) and during insulin infusion (0.2 mU, 2.5 +/- 0.3 v 2.9 +/- 0.4; 1.0 mU, 4.7 +/- 0.3 v 5.3 +/- 1.1 mumol.kg-1.min-1 for hypertensive and control groups, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Glucose/metabolism , Hypertension/physiopathology , Insulin Resistance , Insulin/blood , Liver/metabolism , 3-Hydroxybutyric Acid , Blood Glucose/metabolism , Fatty Acids, Nonesterified/blood , Female , Glucose Clamp Technique , Glucose Tolerance Test , Glycerol/blood , Humans , Hydroxybutyrates/blood , Hypertension/metabolism , Kinetics , Lactates/blood , Male , Middle Aged , Pyruvates/blood , Reference ValuesSubject(s)
Hypothyroidism/epidemiology , Adult , Aged , Blood Chemical Analysis , Cholesterol/blood , Female , Hospitals , Humans , Hypothyroidism/drug therapy , Incidence , Middle Aged , Referral and Consultation , Thyrotropin/blood , Thyroxine/blood , Thyroxine/therapeutic use , United Kingdom/epidemiologyABSTRACT
The World Health Organization (1985) criteria allow evaluation of the oral glucose tolerance test using venous or capillary whole blood or plasma glucose measurements. However, the empirical factors used for interconversion may not reflect observed differences, especially during pregnancy, causing inconsistent classification. To investigate how choice of sample would influence the interpretation of results, venous and capillary blood was taken during oral glucose tolerance tests in 36 pregnant women at risk of gestational diabetes and in 21 non-pregnant control subjects. Glucose was measured on whole blood and plasma by a glucose oxidase method. No cases of gestational diabetes were identified. Eight subjects had gestational Impaired Glucose Tolerance using either venous plasma or venous whole blood results, but only five were similarly classified with capillary whole blood and only four using capillary plasma. Plasma-whole blood differences (venous 0.6 +/- 0.2 (+/- SD) mmol l-1, capillary 0.7 +/- 0.3 mmol l-1) and capillary-venous differences (plasma 0.5 +/- 0.4, whole blood 0.4 +/- 0.5 mmol l-1) at 2 h were lower (all p less than 0.05) than in the WHO criteria (1.1 mmol l-1). When compared with venous plasma, capillary measurements may give a lower incidence and venous whole blood measurements a higher incidence of Impaired Glucose Tolerance in pregnancy.
Subject(s)
Blood Glucose/analysis , Blood Specimen Collection/methods , Glucose Tolerance Test , Pregnancy in Diabetics/diagnosis , Adult , Capillaries , Female , Humans , Pregnancy , Pregnancy in Diabetics/blood , Veins , World Health OrganizationABSTRACT
The use of tritiated glucose tracers may result in underestimation of glucose turnover during hyperinsulinaemic clamps giving paradoxical negative endogenous glucose production rates. While mathematical modelling errors in the analysis of tracer data are major determinants of this underestimate in the non-steady state, the relative importance of tracer contamination under these conditions remains in doubt. We have used high performance liquid chromatography to assess the possible contribution to this problem of a labelled tracer impurity found in [6-3H]glucose. In conventional 4 h hyperinsulinaemic clamps performed in six normal subjects, labelled impurity increased as a percentage of the neutral plasma radioactivity fraction from 5.3 +/- 0.9% after a 2 h equilibration period (0 min) to 13.5 +/- 2.2% at 120 min and 15.4 +/- 2.4% at 240 min, as plasma glucose specific activities fell following the infusion of insulin. Negative endogenous glucose production rates were observed both at 90-120 min (-8.8 +/- 1.6 mumol.kg-1min-1) and at 210-240 min (-8.5 +/- 1.4 mumol.kg-1min-1) implying a persistent underestimate in isotopically determined glucose appearance rate. Using chromatography data to correct for impurity increased glucose appearance rates by 7.9 +/- 2.1% at 120 min and 11.0 +/- 2.5% at 240 min. Purified tracer was then used for a further six clamps. When the conventional protocol was used with unlabelled glucose infusion an obvious negative error persisted only at 90-120 min. In contrast, labelled infusions gave exclusively positive values for endogenous glucose production.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Glucose/metabolism , Adult , Blood Glucose/analysis , Chromatography, High Pressure Liquid , Drug Contamination , Female , Glucose/analysis , Glucose Clamp Technique , Humans , Hyperinsulinism/metabolism , Male , TritiumABSTRACT
Two new reagent strips have recently been introduced for blood glucose measurement by direct visual reading. Results obtained with these strips (Glucostix and Hypogard GA) were compared with those obtained using other commonly employed strips (BM-Test-Glycemie 1-44 and Visidex II) and a standard laboratory method. Blood glucose estimations were performed on samples of venous blood drawn from 125 patients attending the diabetic clinic using each of the four strips and the laboratory method. Results obtained with the strips correlated with the laboratory values as follows: BM-Test-Glycemie 1-44, r=0.93; Glucostix r=0.93; Hypogard GA r=0.87 and Visidex II r=0.92. The lower correlation with Hypogard GA reflected consistent underestimation of the laboratory value (slope of regression line = 0.63). Readings in error by 20% or more were: BM-Test-Glycemie 1-44, 14%; Glucostix, 15%; Hypogard GA, 31%, and Visidex II, 14%. With Hypogard GA strips, 57% of readings above 16 mmol/l were inaccurate. We conclude that Hypogard GA strips cannot be recommended for direct visual reading. Acceptable results may, however, be obtained using the other three strips.Reagent strips allow reasonably accurate determinations of blood glucose concentrations when used with a reflectance meter.(1, 2) Nevertheless many diabetic patients prefer to read the reagent strips visually. This method avoids the problems associated with meter calibration, is cheaper and also is more portable. Direct visual readings with BM-Test-Glycemie 1-44 (Boehringer Corporation) and Visidex II (Ames) have been shown to be acceptable in the hands of medical and technical personnel.(3, 4) Recently two new reagent strips have been marketed, Hypogard GA (Hypogard UK Ltd) and Glucostix (Ames), and it is claimed that they are also suitable for direct visual reading. To test the validity of these claims, we have compared results obtained using the newer strips with readings from BM-Test-Glycemie 1-44 and Visidex II and with a standard laboratory method.